Cardiovascular risk reduction in the extreme elderly

Journal of Pharmacy Practice and Research

Volumn 43, Issue 1, 2013, Pages 62-68

  Parikh, Seema ^a   Sharkey, Kerith ^a   Workman, Barbara ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LIPID; LISINOPRIL; METOPROLOL; NEBIVOLOL; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NORTRIPTYLINE; PERINDOPRIL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; VARENICLINE;

AGED; AGING; ANTIHYPERTENSIVE THERAPY; BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONGESTIVE HEART FAILURE; DIET THERAPY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BILAYER; LIPID BLOOD LEVEL; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; SYSTOLIC HEART FAILURE; TOBACCO DEPENDENCE;

EID: 84876532493     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2013.tb00220.x     Document Type: Review

References (69)

1. Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Cardiovascular disease series. Cat. no. CVD 53. Canberra: Australian Institute of Health and Welfare; 2011.
2. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735-43.
3. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, et al. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation 2011; 124: 967-90.
4. Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008; 168: 418-24.
5. United Nations Department of Economic and Social Affairs, Population Division. World population prospects: the 2004 revision. New York: United Nations; 2005.
6. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-72.
7. Bulpitt CJ. Secondary prevention of coronary heart disease in the elderly. Heart 2005; 91: 396-400.
8. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung 2011; 61: 221-8.
9. Protogerou AD, Safar ME, Iaria P, Safar H, Le Dudal K, Filipovsky J, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007; 50: 172-80.
10. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
11. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, Schron EB, Lindholm LH, Fagard R, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens 2010; 28: 1366-72.
12. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3.
13. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
14. National Institute for Health and Clinical Excellence. Clinical management of primary hypertension in adults. NICE clinical guideline 127. London: National Institute for Health and Clinical Excellence; 2011. Available from .
15. Department of Health and Ageing. General statement for lipid-lowering drugs prescribed as pharmaceutical benefits. Canberra: Department of Health and Ageing. Available from .
16. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010; 39: 674-80.
17. Galioto A, Dominguez LJ, Pineo A, Ferlisi A, Putignano E, Belvedere M, et al. Cardiovascular risk factors in centenarians. Exp Gerontol 2008; 43: 106-13.
18. Perls T, Terry D. Understanding the determinants of exceptional longevity. Ann Intern Med 2003; 139: 445-9.
19. Maciaszek J, Osinski W. Effect of tai chi on body balance: randomized controlled trial in elderly men with dizziness. Am J Chin Med 2012; 40: 245-53.
20. McNamara A, Gunter K. The influence of participation in Better Bones and Balance on skeletal health: evaluation of a community-based exercise program to reduce fall and fracture risk. Osteoporos Int 2011; 23: 1813-22.
21. Appel DW, Aldrich TK. Smoking cessation in the elderly. Clin Geriatr Med 2003; 19: 77-100.
22. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville: US Public Health Service, Office on Smoking and Health; 1990.
23. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 213-17.
24. Connolly MJ. Smoking cessation in old age: closing the stable door? Age Ageing 2000; 29: 193-5.
25. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55: 281-99.
26. US Food and Drug Administration. FDA drug safety communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Silver Spring: US Food and Drug Administration; 2011. Available from .
27. Wolfrum S, Jensen KS, Liao JK. Endothelium dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
28. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
29. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
30. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; Issue 1. Art. No.: CD004816.
31. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008; 51: 37-45.
32. Gransbo K, Melander O, Wallentin L, Lindback J, Stenestrand U, Carlsson J, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010; 55: 1362-9.
33. Alonzo CB. Myths and facts concerning the use of statins in very old patients. Cardiovasc Hematol Disord Drug Targets 2011; 11: 17-23.
34. Coats AJ. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging 2006; 23: 93-9.
35. Yanagisawa S, Suzuki N, Tanaka T. Poor tolerance of beta-blockers by elderly patients with heart failure. Clin Interv Aging 2010; 5: 365-8.
36. Rousseau MF, Chapelle F, Van Eyll C, Stoleru L, Hager D, Van Nueten L, et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996; 2: 15-23.
37. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001; 3: 351-7.
38. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
39. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
40. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
41. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-9.
42. Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults: the cardiovascular health study. Hypertension 1992; 19: 508-19.
43. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
44. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50: 1659-66.
45. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97.
46. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343: 1115-22.
47. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
48. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
49. Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
50. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-60.
51. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
52. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
53. Gambassi G, Lapane KL, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med 2000; 160: 53-60.
54. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin ii-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151: 861-71.
55. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-16.
56. Mahe I, Leizorovicz A, Caulin C, Bergmann JF. Aspirin for the prevention of cardiovascular events in the elderly. Drugs Aging 2003; 20: 999-1010.
57. Ward SA, Demos L, Workman B, McNeil JJ. Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions. Drugs Aging 2012; 29: 251-8.
58. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-35.
59. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
60. Ridker PM, Cook MR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
61. Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H, et al. Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Drugs Aging 2003; 20: 897-903.
62. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care 2002; 8 (22 suppl): S691-S700.
63. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988 2: 349-60.
64. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare benefi ciaries. Patterns of use and outcomes. Circulation 1995; 92: 2841-7.
65. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992; 268: 1417-22.
66. Bene J, Liston R. Clinical trials should be designed to include elderly people. BMJ 1998; 316: 1905.
67. Enkvist A, Ekstrom H, Elmstahl S. What factors affect life satisfaction (LS) among the oldest-old? Arch Gerontol Geriatr 2012; 54: 140-5.
68. Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010; 58: 650-7.
69. Elliott RA. Problems with medication use in the elderly: an Australian perspective. J Pharm Pract Res 2006; 36: 58-66.